Du är här

2016-02-11

Bionor Pharma ASA: Bionor Pharma ASA completes extraordinary general meeting

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Bionor Pharma ASA completes extraordinary general meeting

(Oslo, Norway, 11 February 2016) Bionor Pharma ASA ("Bionor" or the "Company",
ticker "BIONOR") has completed the Extraordinary General Meeting (EGM) today
which approved the Private Placement and Repair Issue announced on 27 January
2016. As proposed by the Company's majority shareholder at the EGM, the EGM
resolved not to allow oversubscription in the Repair Issue.

Please see the attached minutes from the meeting in Norwegian and English
translation as well as a company presentation from the meeting.

The Repair Issue is subject to a prospectus being approved by the Norwegian
Financial Supervisory Authority and published by the Company. All details
about the Repair Issue will be set out in the prospectus, expected to be
published on or about 16 February 2016.

This information is published in accordance with the requirements of the
Continuing Obligations.

Further information

David Horn Solomon, President and CEO, +45 22 20 63 00, dhs@bionorpharma.com
Jens Krøis, CFO, +45 20 80 16 68, jk@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39
03,jfr@bionorpharma.com

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by reducing latent HIV reservoir and further demonstrated
control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available
atwww.bionorpharma.com.

Bionor completes EGM
http://hugin.info/131219/R/1985568/728225.pdf
Bionor_EGM_Minutes_Feb2016
http://hugin.info/131219/R/1985568/728226.pdf
Bionor EGM Presentation
http://hugin.info/131219/R/1985568/728230.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#1985568

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.